Composition for preventing or treating cellular senescence-related diseases comprising salinomycin as effective component

Patent metadata

Field	Value
Publication number	US-12083093-B2
Application number	US-201917413088-A
Country	US
Kind code	B2
Filing date	Oct 11, 2019
Priority date	Dec 13, 2018
Publication date	Sep 10, 2024
Grant date	Sep 10, 2024

Abstract

The present invention relates to a composition for preventing or treating cellular senescence-associated diseases comprising salinomycin as an active ingredient, which acts differently depending on the type of senescent cells, and it was confirmed that salinomycin exhibits a senomorphics effect of restoring the function and morphology of fibroblasts and vascular endothelial cells in which senescence is induced and exhibits a senolytics effect of selectively killing aging-induced retinal pigmented epithelial cells, and exhibits a senomorphics effect of restoring the function and morphology of cells, and thus the salinomycin acts differently depending on the type of cells to effectively prevent or treat senile eye disease, tissue fibrosis disease, atherosclerosis, osteoarthritis, degenerative brain disease, chronic skin damage, obesity and diabetes caused by cellular aging and can be provided as a composition for life extension.

First claim

The invention claimed is:

1. A method for restoring function of a senescent cell to a normal cell comprising administering a pharmaceutical composition comprising salinomycin as an active ingredient to a subject in need of restoring function of the senescent cell to the normal cell,
wherein the senescent cell is selected from the group consisting of a fibroblast and a vascular endothelial cell, and
wherein a senescence is induced by drug treatment or subculture in the senescent cell.

2. A method for killing a senescent cell comprising administering a pharmaceutical composition comprising salinomycin as an active ingredient to a subject in need of killing the senescent cell,
wherein the senescent cell is a retinal pigmented epithelial cell, and
wherein a senescence is induced by drug treatment or subculture in the retinal pigmented epithelial cell.

3. A method for treating a tissue fibrosis comprising administering a pharmaceutical composition comprising salinomycin as an active ingredient to a subject in need of treating tissue fibrosis.

4. The method of claim 3 , wherein the salinomycin selectively kills a senescent cell or restores function or shape of the senescent cell to a normal cell to treat the tissue fibrosis.

5. The method of claim 3 , wherein the tissue fibrosis is selected from the group consisting of a renal fibrosis, a pulmonary fibrosis, and a peritoneal fibrosis.

6. A method for improving aging comprising administering a pharmaceutical composition comprising salinomycin as an active ingredient to a subject in need of the improving aging.

Assignees

• Univ Yeungnam Res Cooperation Foundation

Inventors

• Kim Jae-Ryong
• Kim Eok-Cheon
• Jung Kyong-Jin
• Son You Lim

Classifications

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61P13/12 Primary

  of the kidneys · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P19/04

  for non-specific disorders of the connective tissue · CPC title